Ohio State Navbar

Directory

Robert Baiocchi, MD, PhD


Staff photo

B404 Starling Loving Hall
320 West 10th Avenue
Columbus, OH 43210

Phone: (614) 685-5667

Email: baiocchi.1@osu.edu

 

Current OSU Appointments

Associate Professor, Hematology

Physician, FGP-Hematology

 

Advising Narrative

Roessler Scholar 2006-2007; American College of Physicians, (OH Chapter) 4th place Basic Research Presentation.
Senior Honors Thesis granted 6/06; Senior Research Scholar Summer 2006, Presidents' Salute for Undergraduate Academic Achievment 5/07; Denman Research Forum: 2nd Place Medical Sciences.
Mayers Scholarship Summer 2006; TELR Scholar OSU 2006; Denman Research Forum: 1st Place Biological Sciences.
Senior Research Scholar Summer 2006; Best Poster Biological Sciences Undergraduate Colloquium 2007; Denman Research Forum: 3rd Place Biological Sciences.
Senior Honors Thesis granted 5/10; Arts and Sciences Undergraduate Research Scholarship Recipient 5/08; Presidents' Salute for Undergraduate Academic Achievement 5/10; Biological, Mathematical and Physical Sciences; BMPS Undergraduate Research Forum: Best Poster; Denman Research Forum: 2nd Place Health Professions - Laboratory/Cellular 5/10, 2011 Roessler Scholar
Senior Honors Thesis 2005
Grever Summer Program for Biomedical Sciences, 2008; Phi Kappa Phi Undergraduate Enrichment Award 2008
2009 OSU Undergraduate Research Scholarship2010 Denman2010 ASH Trainee Research Award2010-2011 Pelotonia Undergraduate Fellowship
6/07 Senior Honors Thesis granted 2006 Senior Research Scholar Summer 5/07 Presidents' Salute for Undergraduate Academic Achievment 2007 Denman Research Forum: 2nd Place Medical Sciences.2010-2011 Roessler Scholar
Senior Honors Thesis granted 6/06; Senior Research Scholar Summer 2006, Presidents' Salute for Undergraduate Academic Achievment 5/07; Denman Research Forum: 2nd Place Medical Sciences.2010 Internal Medicine Summer Research Program; 2010 Peletonia Medical Student Scholar
OSU Undergraduate Research Scholarship 2009, Presidential Salute 2010
2009 OSU Undergraduate Research Scholarship 5/07 Presidents' Salute for Undergraduate Adademic Achievement2010 Denman Research Forum: 2nd Place Medical Sciences
2011 The Ohio State University Honors and Scholars Research Scholarhship, 2011 The Ohio State University Arts and Sciences Research Scholarship, 2011 Solar Foundation Research Grant
2011Stanford University MS Bioengineering2011 University of California at San Francisco Medical School
2011-12Undergraduate Research Scholarship Award, The Ohio State University, Arts and Sciences Honors Program

Roessler Scholar 2006-2007; American College of Physicians, (OH Chapter) 4th place Basic Research Presentation.
Senior Honors Thesis granted 6/06; Senior Research Scholar Summer 2006, Presidents' Salute for Undergraduate Academic Achievment 5/07; Denman Research Forum: 2nd Place Medical Sciences.
Mayers Scholarship Summer 2006; TELR Scholar OSU 2006; Denman Research Forum: 1st Place Biological Sciences.
Senior Research Scholar Summer 2006; Best Poster Biological Sciences Undergraduate Colloquium 2007; Denman Research Forum: 3rd Place Biological Sciences.
Senior Honors Thesis granted 5/10; Arts and Sciences Undergraduate Research Scholarship Recipient 5/08; Presidents' Salute for Undergraduate Academic Achievement 5/10; Biological, Mathematical and Physical Sciences; BMPS Undergraduate Research Forum: Best Poster; Denman Research Forum: 2nd Place Health Professions - Laboratory/Cellular 5/10, 2011 Roessler Scholar
Senior Honors Thesis 2005
Grever Summer Program for Biomedical Sciences, 2008; Phi Kappa Phi Undergraduate Enrichment Award 2008
2009 OSU Undergraduate Research Scholarship2010 Denman2010 ASH Trainee Research Award2010-2011 Pelotonia Undergraduate Fellowship
6/07 Senior Honors Thesis granted 2006 Senior Research Scholar Summer 5/07 Presidents' Salute for Undergraduate Academic Achievment 2007 Denman Research Forum: 2nd Place Medical Sciences.2010-2011 Roessler Scholar
Senior Honors Thesis granted 6/06; Senior Research Scholar Summer 2006, Presidents' Salute for Undergraduate Academic Achievment 5/07; Denman Research Forum: 2nd Place Medical Sciences.2010 Internal Medicine Summer Research Program; 2010 Peletonia Medical Student Scholar
OSU Undergraduate Research Scholarship 2009, Presidential Salute 2010
2009 OSU Undergraduate Research Scholarship 5/07 Presidents' Salute for Undergraduate Adademic Achievement2010 Denman Research Forum: 2nd Place Medical Sciences
2011 The Ohio State University Honors and Scholars Research Scholarhship, 2011 The Ohio State University Arts and Sciences Research Scholarship, 2011 Solar Foundation Research Grant
2011Stanford University MS Bioengineering2011 University of California at San Francisco Medical School
2011-12Undergraduate Research Scholarship Award, The Ohio State University, Arts and Sciences Honors Program

Academic Advising

2007 - present , The Ohio State University.
2013 Lisa Kim, The Ohio State University. Graduated 0.
2015 Timothy Vorhees, The Ohio State University. Graduated 0.
2016 Kelsey Chatman, The Ohio State University. Graduated 0.
2016 MIchael Harris, Miami University of Ohio. Graduated 0.
2016 Zach Smith, Miami University of Ohio. Graduated 0.
2006 - 2009 Rohit Tiwari, The Ohio State University. Design of Nucleoside Analogues to Target Herpes Virus Thymidine Kinase
2014 - 2015 Andy M., The Ohio State University. Graduated 2015.
 

Books

Cytokine regulation of Epstein-Barr virus associated lymphoproliferative disease in the severe combined immune deficient mouse-human chimeric model.

 

Licenses

1997 - present Board Certification: National Board of Medical Examiners
1999 - present Board Certification: National Board of Medical Examiners
2000 - present Board Certification: National Board of Medical Examiners
2001 - present Medical License: State Medical Board of Ohio
2003 - present Board Certification: American Board of Internal Medicine
2009 - present Board Certification: American Board of Internal Medicine
 

Chapters in Books

Immundeficiency Associated Lymphomas

Classification of malignant lymphoid disorders

 

Conferences

Phenotypic characteristics of "prolymphocytoid" transformmed (CLL/PLL) chronic lymphocytic leukemia (CLL) cells

LOW-DOSE IL-2 PREVENTS THE DEVELOPMENT OF EPSTEIN-BARR VIRUS-ASSOCIATED LYMPHOPROLIFERATIVE DISORDER IN THE SCID-HUMAN MOUSE

The c-kit ligand suppresses apoptosis of human natural killer cells in serum-free media through the upregulation of BCL 2

Human IL-10 and BCL-2 are abberantly expressed in severe combined immune deficient mouse/human chimeras with Epstein Barr virus lymphoproliferative disease

Epstein-barr virus-associted lymphoproliferative disease (EBV-LPD) in the severe combined immune deficient human/mouse model: Prevention with low-dose interleukin-2 supresses production of human interleukin-6 and interleukin-10

Analysis of FAS/CD95 expression and function in Epstein-Barr virus (EBV)-associated human B cell tumors.

A successful endogenous human immune response to transplantation-associated Epstein-barr virus (EBV) monoclonal B-cell lymphoma

Combination cytokine therapy prevents human EBV-associated lymphoproliferative disease (EBV-LPD) in the human-PBL-SCID mouse model: Critical role of human natural killer (NK) cells.

Immunotherapy with low-dose interleukin-2: rationale for prevention of immune-deficiency-associated cancer.

Lymphomagenesis in the severe combined immune deficient mouse engrafted with human lymphocytes: Clues towards the pathogenesis and treatment of AIDS lymphoma (review)

Analysis of T(H)1/T(H)2 cytokine gene profile during low dose IL-2 therapy in patients with AIDS or AIDS lymphoma.

An in vivo model to evaluate an effective antiviral regimen in Epstein-barr virus (EBV)-associated primary central nervous system lymphoma

The combination of rituximab (anti-CD20 mAb) and daily low dose interleukin-2 (IL-2) therapy effectively treats established human Epstein-Barr virus-associated lymphoproliferative disorder (EBV-LPD) in a mouse model of human EBV-LPD.

Cytokine replacement in patients with HIV-1 non-Hodgkin's lymphoma: The rationale for low-dose interleukin-2 therapy

Post-transplant lymphoproliferative disorders following renal allografting: prospective immunological and molecular monitoring identifies correlates of clinical response to reduction of immune suppression and antiviral therapy

Treatment of EBV-transformed B cell lines with depsipeptide results in the induction of a viral thymidine kinase and enhanced susceptibility to antiviral-induced apoptosis.

Combination Antiviral therapy to treat Epstein-barr virus-associated promary central nervous system lymphoma

The histone deacetylase inhibitor depsipeptide (FR901228) selectively induces apoptosis in latency type III Epstein-Barr virus (EBV) transformed lymphoblastoid cells (LCL) and is enhanced by the inhibition of NFkappaB.

IFN-gamma genotype and TGF-beta interactions contribute to EBV-associated lymphoproliferative disorder (EBV-LPD) development

Bexarotene-induced T-cell immunomodulation and response in CTCL.

A novel human CD34(+) subset that constitutively expresses the high affinity interleukin-2 receptor traffics to lymph nodes and differentiates into CD56(Bright) natural killer cells.

Elevated peripheral blood (PB) cytomegalovirus (CMV) viral loads and reduced CD8* t-cell counts are common findings in T-cell lymphomas before systemic therapy

Durable complete response (CR) and suppression of the human T-cell leukemia virus (HTLV-1) viral load (VC) with alemtuzumab in refractory adult T-cell leukemia (ATL).

Combination bortezomib (PS341, Velcade) and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma.

Excessive neurotoxicity in a phase II trial of combined bortezomib and rituximab in patients with relapsed/refractory mantle cell (MCL) and follicular (FL) non-Hodgkin's lymphoma.

Bortezomib-induced down-regulation of KIT is mediated by inhibition of Sp1 and NF-kB in AML1/ETO-positive cells.

Phase I trial of subcutaneous (SQ) alemtuzumab (A) and CHOP in T-cell lymphoma: Preliminary results.

A vaccine-based strategy to enhance Epstein Barr Virus (EBV)-specific T-cell responses to prevent post-transplant lymphoproliferative disorder (PTLD)

Pre-clinical activity of a novel Fc gamma RIIIa engineered CD19 monoclonal antibody in B cell chronic lymphocytic leukemia and acute lymphoblastic leukemia

A phase I trial of subcutaneous (SQ) dose-escalated alemtuzumab in patients with T-Cell lymphoproliferative disorders (T-LPD)

A Phase I Evaluation of Low Dose Decitabine Targeting DNA Hypermethylation in Patients with Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL): Dose-Limiting Myelosuppression without Evidence of Hypomethylation

Combination Anti-CD74 (Milatuzumab) and CD20 (Rituximab) Monoclonal Antibody Therapy Has in Vitro and in Vivo Activity in Mantle Cell Lymphoma

CT-011, a monoclonal PD-1 blocking antibody, enhances natural killer cell activation and cytotoxicity against multiple myeloma

FEASIBILITY OF ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION (ALLO-SCT) FOLLOWING REDUCED INTENSITY CONDITIONING (RIC) IN HIV plus PATIENTS WITH HEMATOLOGICAL MALIGNANCIES

Co-Treatment with Milatuzumab (Anti-CD74 mAb) and Rituximab (Anti-CD20 mAb) Results in the Induction of Mantle Cell Lymphoma Cell Death That Is Dependent On Actin Polymerization and Inhibition of NF-Kb.

Evidence of MicroRNA-29b and Sp1/NF kappa B-HDAC Regulatory Network for KIT Expression in KIT-Driven Acute Myeloid Leukemia (AML): Biologic and Therapeutic Implications

FTY720 Demonstrates Promising in-Vitro and in-Vivo Pre-Clinical Activity by Down-Modulation of Cyclin D1 and Pakt in Mantle Cell Lymphoma

A phase I study of flavopiridol using an alternative schedule in patients (pts) with advanced solid tumors

Defining a novel vaccine strategy for Epstien-barr virus-associated post-transplant lymphoproliferative disorder

CD19 Targeting of Lymphoid Malignancies by Novel Fc-Domain Engineered Monoclonal Antibody

Early Evidence of Anti-Lymplioma Activity of the Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH 727965) In Heavily Pre-Treated Low Grade Lymphoma and Diffuse Large Cell Lymphoma Patients

Flavopiridol Can Be Safely Administered Using a Pharmacologically Derived Schedule and Demonstrates Activity In Relapsed and Refractory Non-Hodgkin's Lymphoma

Structure-based computational design of selective, small molecule PRMT5 inhibitors for experimental therapeutics of cancer: Protein modeling, virtual screening and lead validation

A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma

FTY720 Increases CD74 Expression and Sensitizes Mantle Cell Lymphoma Cells to Milatuzumab-Mediated Cell Death

Blood (ASH Annual Meeting Abstract) Abstract # 3498 Oral Presentation

Results of A Phase 1 Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma

The Prognostic Value of FDG PET/CT Prior to Autologous Stem Cell Transplant in Mantle Cell Lymphoma

Developing a Novel Class of Drug to Inhibit Protein Arginine Methyltransferase 5 (PRMT5) Enzyme Dysregulation in Mantle Cell Lymphoma

Silvestrol Modulates Direct Anti-Tumor Activity Against Epstein-Barr Virus (EBV)-Associated Lymphomas While Sparing Innate and Antigen Specific Adaptive Immunity

Successful Treatment of Primary Central Nervous System Post-Transplant Lymphoproliferative Disorder (PCNS-PTLD) with Zidovudine (AZT), Ganciclovir (GCV), Rituximab and Dexamethasone: A Single-Institution Case Series

Targeting the Cyclin D-CDK4/6-Rb Axis in Mantle Cell Lymphoma with the Novel Translation Inhibitor Silvestrol

Immune Reconstitution and Quality of Life Analyses After Autologous Transplant for Multiple Myeloma

Complex Karyotype (CK) Is Associated with a Shortened Progression-Free Survival (PFS) in Patients (pts) with Newly Diagnosed Mantle Cell Lymphoma (MCL).

Protein Arginine Methyltransferase 5 (PRMT5) Over-Expression Is Essential for Epstein-Barr Virus-Driven B-Cell Transformation

COMPLEX KARYOTYPE (CK) IS ASSOCIATED WITH INCREASED CUMULATIVE INCIDENCE OF RELAPSE (CIR) FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) FOR MANTLE CELL LYMPHOMA (MCL) IN FIRST REMISSION

Phase I Study of AR-42 in Relapsed Multiple Myeloma and Lymphoma.

Complete Response (CR) to Induction Therapy in Patients (pts) with Myc plus and Double Hit Non-Hodgkin's Lymphoma (NHL) Is Associated with Prolonged Progression-Free Survival (PFS).

Utilization of EBV DNA Copy Number Monitoring in Extranodal NK Lymphoma, Nasal Type in Non Asian Patients

Toxicity in patients (pts) age 65 or older with dose-adjusted REPOCH (DA-REPOCH) for untreated diffuse large B-cell lymphoma (DLBCL).

Post Autologous Transplant Vorinostat (SAHA) in High Risk Lymphoma: Phase 1 Study of Vorinostat Maintenance

Busulfan, cyclophosphamide, etoposide is not superior to carmustine, etoposide, cytarabine, mephalan conditioning prior to autologous stem cell transplantation in patients with Hodgkin's lymphoma and is associated with increased toxicity

Protein Arginine Methyltransferase-5 Overexpression Is Frequently Observed in Non-Small Cell Lung Carcinomas

Protein Arginine Methyltransferase-5 Overexpression Is Frequently Observed in Non-Small Cell Lung Carcinomas

Cellular Localization of Protein Arginine Methyltransferase-5 Correlates With Grade of Pulmonary Neuroendocrine Tumors

Developing a first in class of drug to inhibit protein arginine methyltransferase 5 (PRMT5) enzyme dysregulation in glioblastoma multiforme.

Protein Arginine Methyltransferase-5 as a Novel Epigenetic Target in Lung Cancer

RADIATION INDUCED PRMT5 EXPRESSION IS REGULATED BY miRNA-96 IN GLIOBLASTOMA

Protein Arginine Methyltransferase 5 Supports MYC, Survivin and Cyclin D1 Activity in Aggressive Lymphomas By Regulating the WNT/beta-Catenin Pathway

Expression of PRMT5 in B-Cell Chronic Lymphocytic Leukemia and Its Significance in Disease Progression and Richter's Transformation

Determination of Optimal Target Antigen and Immune Modulatory Approaches to Improve and Standardize Epstein-Barr Virus-Specific Adoptive T Cell Therapy

Identifying and Targeting Cytotoxic Tumor-Associated Macrophages in Epstein-Barr Virus-Driven Lymphoproliferative Disease

The Epstein-Barr Virus Lytic Protein BZLF1 As a Candidate Target Antigen for Vaccine Development

Epstein-Barr Virus Kinase-Targeted Therapy for Primary Central Nervous System Post-Transplant Lymphoproliferative Disorder

Prognostic implications, predictive value, and latency analysis of Epstein-Barr virus (EBV) DNA in advanced stage cutaneous T-cell lymphoma (AS-CTCL).

Poor Prognostic Effect of CD5 Positivity for Patients with Diffuse Large B-Cell Lymphoma: Results from a Retrospective Single Institution Analysis

Inhibition of PRMT5 results in radiosensitization in lung cancer cell lines

Protein Arginine Methyltransferase 5 Directly Targets and Epigenetically Silences microRNAs miR33b and miR96 to Support Constitutive Cyclin D1 Activity in Non-Hodgkin's Lymphoma

Protein arginine methyltransferase inhibition of malignant gliomas leads to restored chemokine expression and enhanced immune effector function

AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma

Cellular localization of PRMT5 correlates with poor recurrent free survival in triple-negative breast cancer (TNBC)

ROR1 targeted delivery of OSU-2S, a non-immunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle cell lymphoma in-vitro and in-vivo

Role of protein arginine methyltransferase 5 over-expression in HTLV-1-driven cellular transformation and leukemia

The Epstein-Barr Virus Lytic Protein BZLF1 as a Candidate Target Antigen for Vaccine Development

The Role of EBV in Advanced Cases of Cutaneous T-Cell Lymphoma in Prognosis and the Immunologic (PD-1/PD-L1) Milieu

 

Degrees

1989 B.S., State University of New York College at Buffalo

1993 M.S., State University of New York College at Buffalo

1994 Ph.D., State University of New York College at Buffalo

1999 M.D., The Ohio State University

 

Editorial Activities

2005 - 2007 Proceedings of National Academy of Sciences
2007 - present American Journal of Transplantation
2007 American Journal of Hematology
2007 Cancer Research
2007 Blood
2009 - present mAbs
2010 - present Cancer Immunology
2010 - present Immunotherapy
2010 - present Expert Opinion on Pharmacotherapy
2011 - present American Society of Hematology Annual Meeting Abstract Reviewer - Molecular Pharmacology, Drug Resistance
2011 - present Chemotherapy
2011 - present PloS One
2011 - present European Journal of Immunology
2011 - present EMBO Molecular Medicine
2011 - present British Journal of Cancer
2011 American Society of Hematology-Molecular Pharmacology, Drug Resistance
2014 Journal of Acquired Immune Deficiency Syndromes
2015 New England Journal of Medicine
2015 Drugs by Ads International
2015 American Society of Hematology: Lymphoma: Pre-Clinical-Chemotherapy and Biologic Agents
 

Honors

1993 - present Mark Diamond Research Foundation Award.
1994 - present New York State Tuition Scholarship for Graduate Studies.
1994 - present Sigma XI Scientific Research Honor.
1996 - present American Society of Hematology Travel Award.
1996 - present American Society of Hematology Medical Student Scholar.
1996 - present NIH Summer Research Internship in Oncology.
1997 - present American Society of Hematology Travel Award.
1998 - present Landacre Society 3rd Place Oral Presentation. Ohio State University.
1998 - present Landacre Society. Ohio State Univeristy.
1998 - present American Society of Hematology Travel Award. The Ohio State Univeristy.
1998 - present American Society of Hematology Medical Student Scholar. Ohio State University.
1999 - present Department of Internal Medicine Medical Student Research Award. The Ohio State University.
2002 - present NIH T32 Research Fellowship. Ohio State University.
2003 - present NIH Clinical Research Loan Repayment Award.
2004 - present James V. Warren Award for Outstanding Research in Internal Medicine.
2005 - present V Foundation Scholar.
2005 - present NIH Clinical Research Loan Repayment Award.
2007 - present Faculty Sponsor President's Salute Christian Earl.
2007 - present Distinguished Undergraduate Research Mentor. The Undergraduate Research Office.
2007 Faculty Sponsor President's Salute Christian Tyler Earl.
2010 - present Excellence in Teaching Award. Department of Internal Medicine.
2010 - present Faculty Sponsor President's Salute John Ryu.
2011 Innovator of the Year Nomination. The Ohio State University.
2011 Excellence in Teaching Award. Department of Internal Medicine.
2011 Inventor of the Year Nomination. Tech Columbus, Innovation Award Semi-Finalist.
2012 Early Career Innovator of the Year Nomination. The Ohio State University.
2014 Internal Medicine Faculty Teaching Award in Inpatient Medicine. The Ohio State University.
2016 - present America's Top Doctor's, Medical Oncology. Castle Connolly.
2016 - present Unverferth Research Award. The Ohio State University.
2016 Excellence in Teaching Award. The Ohio State University.
 

Journal Articles

 

Reference Works

January 1991 Villalona-Calcero M, Stewart C, Baiocchi RA, Caligiuri MA, Foon KA."Phenotypic characteristics of "prolymphocytoid" transformmed (CLL/PLL) chronic lymphocytic leukemia (CLL) cells." . : 230
January 1993 Baiocchi RA, and Caligiuri MA."Low dose IL-2 prevents the development of Epstein Barr virus associated lymphoproliferative disorder in the hu PBL SCID mouse model" . : 385A
January 1993 Bernstein ZP, Baiocchi RA, Bankert RB, Herzig G, and Caligiuri MA."Low dose IL-2 therapy in HIV associated lymphoma." .
January 1994 Baiocchi RA, Haldar S, Sullivan L, Tan JC, Seiden MV, Narula SK, and Caligiuri MA."Human IL-10 and BCL-2 are abberantly expressed in severe combined immune deficient mouse/human chimeras with Epstein Barr virus lymphoproliferative disease" .
January 1994 Baiocchi RA, Sullivan L, Tan J, Narula S, and Caliguiri MA."Epstein-barr virus-associted lymphoproliferative disease (EBV-LPD) in the severe combined immune deficient human/mouse model: Prevention with low-dose interleukin-2 supresses production of human interleukin-6 and interleukin-10." . : 287
January 1994 Carson WE, Haldar S, Baiocchi RA, and Caligiuri MA."The c-kit ligand suppresses apoptosis of human natural killer cells in serum-free media through the upregulation of BCL 2" . : 3
January 1994 Baiocchi RA, Caliguiri MA."Preventative strategies for EBV-Lymphomagenesis in the hu-PBL-SCID mouse model." .
January 1995 Carson WE, Ross ME, Baiocchi RA, Marian M, Boiani N, Grabstein K, and Caligiuri MA."Endogenous production of interleukin-15 by activated monocytes is critical for optimal production of interferon by human natural killer cells in vitro" . : 79
January 1996 Baiocchi RA, Khatri V, Lindemann MJ, Ross ME, Caprio A, Caprio T, Fenstermaker R, Bernstein ZP, and Caligiuri MA."Analysis of FAS/CD95 expression and function in Epstein-barr virus associated human B cell tumors." . : Suppl 1:504a
January 1996 Baiocchi RA and Caligiuri MA."Cytokine regulation of Epstein-Barr associated lymphoma in the hu-PBL-SCID mouse." .
January 1997 Baiocchi RA,, Khatri V, Lindemann MJ, Ross ME, Caprio AJ, Caprio TV, Fenstermaker RA, Bernstein ZP and Caligiuri MA."Phenotypic and functional analysis of FAS/CD95 expression primary central nervous system lymphoma of patients with the aquired immune deficiency syndrome." .
January 1997 Khatri V,Baiocchi RA, and Caligiuri MA."A successful endogenous human immune response to transplantation-associated Epstein-barr virus (EBV) monoclonal B-cell lymphoma." . : 45
January 1997 Baiocchi RA, Lindemann MJ, Nordone P, and Caligiuri MA."Combination cytokine therapy prevents human EBV-associated lymphoproliferative disease in the human-PBL-SCID mouse model: critical role of human natural killer cells." . : Suppl 1:512a
January 1997 Khatri V, Yu F, Baiocchi RA, Shah M, Zwerling BH, Gould M, Bernstein ZP, and Caligiuri MA."Low dose IL-1 enhances the innate immunity and restores the protective Th1 cytokine profile in patients with AIDS/AIDS lymphoma." . : 99
January 1997 Khatri V, Yu F, Baiocchi RA, Shah M, Zwerling BH, Gould M, Bernstein ZP, and Caligiuri MA."Analysis of Th1/Th2 cytokine gene profile during low dose IL-2 therapy in patients with AIDS or AIDS lymphoma." . : 122
January 1997 Khatri V, Baiocchi RA, and Caligiuri MA."A successful endogenous human immune response to transplantation-associated Epstein-barr virus (EBV) monoclonal B-cell lymphoma." . : 9
January 1999 Baiocchi RA, Carredeguas L, Peng R, and Caliguiri MA."Combination Rituximab/Interleukin-2 therapy prevents human Epstein-barr virus-associated lymphoproliferative disease (EBV-LPD) in the hu-PBL-SCID mouse depleted of murine NK cells." .
January 1999 Baiocchi RA, Peng R, Schmalbrock P, Moeschberger M, Barth R, and Caligiuri MA."An in vivo model to evaluate an effective antiviral regimen in Epstein-barr virus (EBV)-associated primary central nervous system lymphoma." .
January 1999 Schmalbrock P, Chakeres D, Peng R, Caligiuri MA, Baiocchi RA, Stredney D, Sessanna D, and Kwok WC."Comparison of MRI and Histology of a Rat Brain Lymphoma Tumor Model using Volume Graphics" .
January 1999 Baiocchi RA, Peng R, Schalmbrock P, Moeschberger M, Barth R and Caligiuri MA."Combination antiviral therapy for treatment of primary central nervous system lymphoma associated with the Epstein-barr virus: In vivo evaluation in an animal model." .
January 1999 Carrodeguas L, Baiocchi RA, Roychowdhury S, Peng R, and Caligiuri MA."Combination Rituximab/Interleukin-2 therapy effectively treats established human Epstein-Barr virus-associated lymphoproliferative disease (EBV-LPD) in the hu-PBL-SCID mouse depleted of murine NK cells" . : 90A
January 1999 Baiocchi RA, Carson WE, Carrodeguas L, Dierksheide JE, Marsh C, Roychowdhury S, Peng R, and Caligiuri MA."Combination humanized-monoclonal antibody and cytokine therapy for treatment of human malignancy." .
January 2001 Baiocchi RA, Sekula T, Courganti S, Nair V, Roychowdhury S, Pathun M, Nuovo G, Marcucci G, Byrd J, Grever M and Caliguiri M."Treatment of EBV-transformed B cell lines with depsipeptide results in the induction of a viral thymidine kinase and enhanced susceptibility to antiviral-induced apoptosis." .
January 2001 Porcu P, Pelletier RP, Davies EA, Baiocchi RA, Eisenbies CF, Roychowdhury S, Nuovo GJ, Marsh W, Vanbuskirk A, Henry ML, Ferguson RM, and Caliguiri MA."Post-transplant lymphoproliferative disorders following renal allografting: prospective immunological and molecular monitoring identifies correlates of clinical response to reduction of immune suppression and antiviral therapy." .
January 2002 Roychowdhury S, Baiocchi RA, Vourganti S, Bhatt D, Chou JD, Eisenbeis CF, Grever MR, and Caligiuri MA."The histine deacetylase inhibitor depsipeptide (FR901228) selctively induces apoptosis in latency type III Epstein-barr virus (EBV) transformed lymphoblastoid cells (lCL) and is enhanced by the inhibition of NFB." . : 780a
January 2002 Baiocchi RA, Peng R, Roychowdhury S, Vourganti S, Bhatt D, Sekula T, Grecula J, Eisenbies C, Procu P, and Caligiuri MA."Combination Antiviral therapy to treat Epstein-barr virus-associated promary central nervous system lymphoma." . : 7a
January 2004 Freud AG, Becknell B, Roychowdhury S, Mao HC, Ferketich AK, Nuovo GJ, Hughes TL, Marburger TB, Sung J, Baiocchi RA, Guimond M and Caliguiri MA."A novel human CD34(+) subset that constitutively expresses the high affinity interleukin-2 receptor traffics to lymph nodes and differentiates into CD56 bright natural killer cells." . : 314
January 2004 Porcu P, Baiocchi RA, Buckner M, Byrd JC, Magro CM."Bexarotene-induced t-cell immunomodulation and response in CTCL." . : 744
January 2005 Wadehra N, Lin T, Ryan T, Schneider A, Pepple A, Johnston J, Dalton J, Banks A, Eisenbeis CF, Lai R, Byrd JC, Blum K, Baiocchi RA.."Combination bortezomib (PS341, Velcade) and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma" .
January 2005 Mone A, Puhalla S, Whitman S, Baiocchi RA, Cruz J, Vukosavljevic T, Banks A, Eisenbies C, Byrd JC, Caliguiri MA and Porcu P."Durable hematological complete response and suppression of HTLV-1 viral load following Alemtuzumab in AZT/IFN refatory adult T-cell leukemia." .
January 2005 Grady T, Nelson M, Staub A, Tucker M,Baiocchi RA, Nuovo G, Magro C, and Porcu P."Elevated peripheral blood (PB) cytomegalovirus (CMV) viral loads and reduced CD8* t-cell counts are common findings in T-cell lymphomas before systemic therapy." .
November 2006 Liu S, Pang J, Yu J, Liu Z, Huynh L, Kearney J, Paschka P, Klisovic R, Baiocchi RA, Blum W, Perotti D, Marcucci G.."Bortezomib-induced down-regulation of KIT is medicated by inhibition of Sp1 and NF-kB in AML1/ETO-positive cells." .
January 2006 Blum KA, Lucas MS, Johnston JS, Daloton J, Young D, Baiocchi RA, Lin TS, Procu P, Byrd JC."Excessive Neurotoxicity in a phase II trial of combined bortezomib and rituximab in patients with relapsed/refactory mantle cell (MCL) and follicular (FL) non-Hodgkin's lymphoma." . : 2768
January 2007 Baiocchi RA, Kim D, Yeh E."Histone deacetylase inhibition modulates tumor-specific innate cellular immunity." .
January 2007 Baiocchi RA and Lin K."Syncope as presenting feature in progressive HIV-associated Burkitt's Lymphoma" .
January 2007 Baiocchi RA and Murthy S."Management of aggresive lymphomatoid granulomatosis" .
January 2007 Porcu P, Baiocchi RA, Lin TS, Blum KA, Curtis P, Grever MR, Byrd JC."A phase 1 trial of subcutaneous dose-escalated alemtuzumab in patients with t cell lymphoproliferative disorders" . : 1001A
January 2007 Porcu P, Baiocchi RA, Liu T, Caligiuri MA.""A vaccine-based strategy to enhance Epstein Barr Virus (EBV)-specific T-cell responses to prevent post-transplant lymphoproliferative disorder (PTLD)."" .
January 2007 Lapalombella R, Roda JM, Baiocchi RA, Zhukocksy E, Desjarlais J, Muthusamy N, Byrd, JC."Preclinical activity of a novel fcgRIIIa engineered CD19 monoclonal antibody in B cell CLL and ALL" . : 695a
January 2008 Lin T, Fischer B, Blum K, Porcu P, Kraut E, Baiocchi RA, Moran M, Mitchell M, Grever M, Byrd J.."An active regimen in indolent B-cell lymphoproliferative disorders and mantle cell lymphoma." .
January 2008 Blum K, Baiocchi RA, Alinari L, Lin T, Porcu P, Jones J, Flynn J, Hicks W, Lucas M, Wei L, Johnston J, Byrd J.."Phase II Trial of induction plus maintenance rituximab and bortezomib in patients with relapsed/refactory mantle cell (MCL) and follicular (FL) non-hodgkin's lymphoma." .
January 2008 Alinari L, Hartlein E, Goldenberg D, Lapalombella R, Yan F, Zhang X, Lucas D, Nuthusamy N, Byrd J, Baiocchi RA.."Combination anti-CD74 (Milatuzumab) and CD20 (Rituximab) Monoclonal Antibody therapy has in vitro and in vivo activity in Mantle Cell Lymphoma." .
December 2009 Alinari L, Liu Q, Chen C-S, Yan F, Dalton JT, Lapalombella R, Zhang X, Lin T, Byrd JC, Baiocchi RA Muthusamy N.."FTY720 Demonstrates Promising in-Vitro and in-Vivo Pre-Clinical Activity by Down-Modulation of Cyclin D1 and Pakt in Mantle Cell Lymphoma." . : 3725
December 2009 Awan F, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson D, Cheney C, Mo X, Lehman A, Jones JA, Flynn JM, Jarjoura D, Baiocchi RA, Desjarlais J, Tridandapani S, Caligiuri MA, Muthusamy N, Byrd JC.."CD19 Targeting of Lymphoid Malignancies by Novel Fc-Domain Engineered Monoclonal Antibody" . : 3725
April 2009 Liu T, Wen J, House M, Clark R, Baiocchi RA, Caliguiri MA.."Defining a novel vaccine strategy for Epstien-barr virus-associated post-transplant lymphoproliferative disorder." .
January 2009 Alinari L, Christian B, Yu B, Shin J, Hertlein E, Lapalombella R, Yan F, Lesinski GB, Zhang X, Lozanski G, Muthusamy N, Goldenberg DM, Byrd JC, Baiocchi RA.."Co-Treatment with Milatuzumab (Anti-CD74 mAb) and Rituximab (Anti-CD20 mAb) Results in the Induction of Mantle Cell Lymphoma Cell Death that is Dependent on Actin Polymerization and Inhibition of NF-kB" .
April 2009 Benson D, Chandler J, Mishra A, Baiocchi RA, Yu J, Liu T, Lozenski G, Porcu P, Devine S, Rotem-Yehudar R, Caliguiri M.."CT-011, a monoclonal PD-1 blocking antibody, enhances natural killer cell activation and cytotoxicity against multiple myeloma." .
December 2009 Liu S, Lai C-W, Pang J, Ramasamy S, Schwind S, Wu Y-Z, Hickey C, Yu J, Mishra A, Becker H, Li C, Briesewitz R, Baiocchi RA, Chan KK, Caligiuri MA, Byrd JC, Perrotti D, Garzon R, Marcucci G.."Evidence of MicroRNA-29b and Sp1/NFB-HDAC Regulatory Network for KIT Expression in KIT-Driven Acute Myeloid Leukemia (AML): Biologic and Therapeutic Implications." . : 938
December 2010 Baiocchi RA, Flynn JM, Jones JA, Blum KA, Hofmeister CC, Poon J, Small K, Statkevich P, Grever MR, Bannerji R, and Byrd JC."Early Evidence of Anti-Lymphoma Activity of the Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH 727965) In Heavily Pre-Treated Low Grade Lymphoma and Diffuse Large Cell Lymphoma Patients" . : 3966
October 2010 Cole C, Baiocchi RAChristian B, Gardner M, Smith A, Heerema NA."A Complex Karyotype with a Four=-Way Translocation 47,XX,t(3;12;19;14) (q27;q13;q13.3;q32), del (6) q13),+mar in a patient with Diffuse Large B-Cell Lymphoma" . : 158
December 2010 Jones JA, Andritsos LA, Baiocchi RA, Benson DM., Blum KA, Christian B, DeamD, Flynn JM, Johnson AJ, Phelps MA, Porcu P, Byrd JC and Grever, MR."Flavopiridol Can Be Safely Administered Using a Pharmacologically Derived Schedule and Demonstrates Activity In Relapsed and Refractory Non-Hodgkin’s Lymphoma" . : 2834
December 2010 Christian B, Alinari L, Earl CT, Wilding E, Quinion C, Lustberg M, Benson DM, Jones JA, Byrd JC, Wegener WA, Goldenberg DM, Baiocchi RA, Blum KA."A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin’s Lymphoma" . : 2788
April 2010 Yan F, Alinari L, Lustberg M, Martin LK, Nowicki O, Wu X, Yu B, Gordon K, Wolfson A, Ryu J, Kaur B, Kwon C-H, Lawler S, Nuovo G, Liu S, Marcucci G, Byrd JC, Chiocca EA, Baiocchi RA.."Targeting protein arginine methyltransferase 5 (PRMT5) enzyme over expression in high grade astrocytomas" . : Abstract #1584
April 2011 Nicholas C, Yan F, Peters S, Bill MA, Li P-K, Li C, Fuchs JR, Baiocchi RA, Lesinski GB.."The expression of PRMT5 methyltransferase mediates cell survival and metastatic phenotype in malignant melanoma." .
December 2011 Alinari L, Mahoney E, Patton JT, Zhang X, Huynh L, Earl CT, Mani R, Mao Y, Yu B, Towns WH, Chen C-S, Goldenberg DM, Blum KA, Byrd JC, Muthusamy N, Prætorius-Ibba M, Baiocchi RA."FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death" .
December 2011 Alinari L, Edwards R, Prince C, Towns W, Mani R, Lehman A, Zhang X , Jarjoura D, Pan L, Kinghorn AD, Grever MR, Baiocchi RA, Lucas DM."Targeting the Cyclin D - CDK4/6 - Rb Axis in Mantle Cell Lymphoma with the Novel Translation Inhibitor Silvestrol" .
December 2011 Cohen JB, Hall N, Ruppert AS, Jones JA, Porcu P, Baiocchi RA, Penza S, Benson DM, Jr, Andritsos LA, Flynn JM, Devine SM, Blum KA.."The Prognostic Value of FDG PET/CT Prior to Autologous Stem Cell Transplant in Mantle Cell Lymphoma" .
December 2011 Martin K, Lustberg ME, Yan F, Patton JT, Porcu P, Nuovo G, Cavaliere R, Baiocchi RA."Successful treatment of Primary Central Nervous System Post-Transplant Lymphoproliferative Disorder (PCNS-PTLD) with Zidovudine (AZT), Ganciclovir (GCV), Rituximab and Dexamethasone: a Single-Institution Case Series" .
July 2011 Lucas DM, Alinari L, Patton JT, Kinghorn AD, Baiocchi RA, Grever MR.."The Protein Synthesis Inhibitor Silvestrol Has In Vitro and In Vivo Efficacy in Aggressive B-cell Malignancies" .
December 2011 Lustberg ME, Pelletier R, Porcu O, Martin S,Baiocchi RA."Risk factors for Post-transplant lymphoproliferative disorder in solid organ transplant recipients" .
December 2011 Yan F, Smith P, Alinari L, Karkhanis V, Tae S, Patton JT, Wilding EE, Gordon K, Manhasenan K, Bhasin D, Agostinelli C, Pileri S, Byrd JC, Sif S, Li P-K, Li C, Baiocchi RA."Developing a novel class of drug to inhibit protein arginine methyltransferase 5 (PRMT5) enzyme dysregulation in mantle cell lymphoma." .
December 2011 Patton JT, Lustberg ME, Garman SL, Kinghorn AD, Pan L, Lucas DM, Grever MR, Baiocchi RA."Silvestrol Modulates Direct Anti-tumor Activity Against Epstein-Barr Virus (EBV)-Associated Lymphomas while Sparing Innate and Antigen Specific Adaptive Immunity" .
December 2011 Christian B, Alinari L, Jones JA, Benson DM Jr, Flynn JM, Porcu P, Lustberg ME, Phelps M, Poi M, Chung D, Quinion C, Byrd JC, Wegener W, Goldenberg DM, Baiocchi RA, Blum KA.."Results of A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma" .
December 2012 Cohen JB, Geyer S, Lozanski G, Zhao X, Heerema NA, Jones JA, Porcu P, Christian B, Baiocchi RA, Maddocks K, Flynn JM, Devine SM, Blum KA."Complete Response (CR) to Induction Therapy in Patients (pts) with Myc+ and Double Hit Non-Hodgkin's Lymphoma (NHL) Is Associated with Prolonged Progression-Free Survival (PFS)." .
December 2012 Hofmeister CC, Bowers MA, Baiocchi RA, Lozanski G, Humphries K, Blum KA, Porcu P, Penza S, Greenfield CN, Sell M, Earl CT, Zitesman J, Quinion C, Lustberg ME, Andritsos LA, Devine SM."Post Autologous Transplant Vorinostat (SAHA) in High Risk Lymphoma: Phase 1 Study of Vorinostat Maintenance." .
May 2012 Stephens DM, Ruppert AS, Christian B, Jones JA, Flynn JM, Porcu P, Baiocchi RA, Byrd JC, Dotson EK, Crawford BS, Blum KA."Toxicity in patients (pts) age 65 or older with dose-adjusted REPOCH (DA-REPOCH) for untreated diffuse large B-cell lymphoma (DLBCL)" .
December 2012 Hofmeister CC, Bowers MA, Bingman A, Lozanski G, Baiocchi RA, Falk W, Benson DM Jr., Efebera YS, Humphries K, Sell M, Greenfield CN, Lustberg ME, Vaughn JL, Earl CT, Geyer S, Devine SM.."Immune Reconstitution and Quality of Life Analyses After Autologous Transplant for Multiple Myeloma." .
December 2012 Alinari L, Yan F, Smith P, Patton JT, Quinion C, Yu B, Earl CT, Lustberg ME, Villagomez L, Hertlein EK, Byrd JC, Ayers L, Motiwala T, Majumder S, Li C, Sif S, Jacob ST, Baiocchi RA."Protein Arginine Methyltransferase 5 (PRMT5) Over-Expression Is Essential for Epstein-Barr Virus-Driven B-Cell Transformation." .
December 2012 Cohen JB, Ruppert AS, Heerema NA, Jones JA, Porcu P, Baiocchi RA, Christian B, Byrd JC, Flynn JM, Penza S, Andritsos LA, Devine SM, Blum KA."Complex Karyotype (CK) Is Associated with a Shortened Progression-Free Survival (PFS) in Patients (pts) with Newly Diagnosed Mantle Cell Lymphoma (MCL)" .
May 2012 Nicholas C, Yang J, Peters SB, Baiocchi RA, Yan F, Sif S, Tae S, Young GS, Grever MR, Lesinski GB."PRMT5 is upregulated in malignant and metastatic melanoma, and regulates expression of the MITF transcription factor" .
December 2012 Hofmeister CC, Liu Z, Bowers MA, Porcu P, Flynn JM, Christian B, Baiocchi RA, Benson DA Jr, Andritsos LA, Greenfield CA, Sell M, Geyer S, Byrd JC, Grever MR."Phase I Study of AR-42 in Relapsed Multiple Myeloma and Lymphoma" .
December 2012 Welliver MX, Salem G, Ruppert AS, Otto BA, Baiocchi RA, Porcu P."Utilization of EBV DNA Copy Number Monitoring in Extranodal NK Lymphoma, Nasal Type in Non-Asian Patients" .
December 2013 Patton JT, Hartlage AS, Pan L, Lustberg ME, Drohan CM, Martin MF, Kinghorn AD, Caligiuri MA, Grever MR, Lucas DM, Baiocchi RA."Silvestrol Modulates Indirect Anti-Tumor Activity and Potentiates Immune Response to Epstein-Barr Virus-Driven Lymphoproliferative Disease" .
April 2013 Tarighat SS, Radomska H, Lai H, Mahasenan K, Perrotti D, Garzon R, Caligiuri M, Li C, Blum W, Marcucci G, Baiocchi RA.."Preclinical and Pharmacological Activities of Protein Arginine Methyltransferase 5(PRMT5) Enzyme Inhibition in Acute Myeloid Leukemia" .
April 2013 Yan F, Gordon K, Mahasenan K, Lustberg M, Alinari L, Kaur B, Li C, Baiocchi RA."Developing a first in class of drug to inhibit protein arginine Methyltransferase 5 (PRMT5) enzyme dysregulation in glioblastoma multiforme" .
December 2013 Roach N, Cannon M, El-Gamal D, Desai PC, Kraut EH, Bradner JE, Lapalombella, Baiocchi RA."The PRMT5 Enzyme To Induce -Globin Gene Derepression In Sickle Cell Anemia." .
June 2014 Haverkos BM, Hemminger J, Geyer SM, Bingman A, VanDuesen K, Lustberg M, Wong H. Gru A. Ambinder R, Baiocchi RA, Porcu P."Prognostic implications, predictive value and latency analysis of Epstein-Bar virus (EBV) DNA in advanced stage cutaneous T-cell lymphoma (AS-CTCL)" .
December 2014 Mitchell ML, Patton JT, O'Donnell L, Baiocchi RA.."Determination of Optimal Target Antigen and Immune Modulatory Approaches to Improve and Standardize Epstein-Barr Virus-Specific Adoptive T Cell Therapy." .
December 2014 El-Gamal D, LaFollette TD, Lai H, Chenglong L, Sampath D, Lehman A, Yu L, Byrd JC, Baiocchi RA, Lapalombella R."Expression of PRMT5 in B-Cell Chronic Lymphocytic Leukemia and Its Significance in Disease Progression and Richter's Transformation." .
December 2014 Patton JT, Mitchell ML, Pan L, Kinghorn AD, Grever M, Lucas DM, Baiocchi RA."Identifying and Targeting Cytotoxic Tumor-Associated Macrophages in Epstein-Barr Virus-Driven Lymphoproliferative Disease" .
December 2014 Hartlage AS, Liu T, Patton JT, Garman SL, Zhang X, Kurt H, Lozanski G, Lustberg ME, Caligiuri MA, Baiocchi RA."The Epstein - Barr virus Lytic Protein BZLF1 As a Candidate Target Antigen for Vaccine Development." .
December 2014 Chung J, Karkhanis V, Sif S, Baiocchi RA."Protein Arginine Methyltransferase 5 Supports MYC, Survivin and Cyclin D1 Activity in Aggressive Lymphomas By Regulating the WNT/β-Catenin Pathway" .
December 2014 Karkhanis V, Elemento O, Di Liberto M, Chen-Kiang S, Sif S, Baiocchi RA."Protein Arginine Methyltransferase 5 Directly Targets and Epigenetically Silences microRNAs miR33b and miR96 to Support Constitutive Cyclin D1 Activity in Non-Hodgkin’s Lymphoma" .
December 2014 Dugan J, Haverkos BM, Martin LK, Martin MF, Lustberg ME, Patton JT, Nuovo G, Yan F, Cavaliere R, Kenney SC, Fingeroth J, Lozanski G, Ramos JC, Porcu P, Caligiuri MA, Baiocchi RA.."Epstein-Barr Virus Kinase-Targeted Therapy for Primary Central Nervous System Post-Transplant Lymphoproliferative Disorder" .
December 2014 Alinari L, Gru A, Quinion C, Huang Y, Jones JA, Devine SM, Maddocks KJ, Christian B, Baiocchi RA, Blum KA."Poor Prognostic Effect of CD5 Positivity for Patients with Diffuse Large B-Cell Lymphoma: Results from a Retrospective Single Institution Analysis" .
February 2014 Kumar B, Cipolla MJ, Brown NV, Wakely PE, Yan F, Schmitt AC, Kumar P, Baiocchi RA, Teknos TN."High Expression of PRMT5 and Cyclin D1 is associated with poor outcome in oropharyngeal squamous cell carcinoma patients and is inversely associated with p16 status" .
December 2014 Karkhanis V, Elemento O, Di Liberto M, Chen-Kiang S, Sif S, Baiocchi RA."Protein Arginine Methyltransferase 5 Directly Targets and Epigenetically Silences microRNAs miR33b and miR96 to Support Constitutive Cyclin D1 Activity in Non-Hodgkin’s Lymphoma" .
June 2016 Teknos T, Old MO, Grecula JC, Agrawal A, Ozer E, Carrau R, Kang S, Rocco JW, Blakaj D, Diavolitis V, Baiocchi RA, Kumar B, Savvides P."A phase 1 trial of vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced stage head and neck squamous cell carcinoma" .
August 2016 Smith E, Stiff A, Patton JT, Carson WE, Lapalombella R, and Baiocchi RA."BET bromodomain inhibition selectively targets the Epstein-Barr virus oncogene LMP1 while promoting virus-specific, adaptive anti-tumor activity" .
December 2016 Smith PL, Yan F, Patton JT, Alinari L, Karkhanis V, Ayers L, Muthusamy N, Mishra A, Ahmed E, Sif S, Lapalombella R, Baiocchi RA.."PRMT5 Transgenic Mice Develop Aggressive Lymphoblastic Lymphomas" .
December 2016 Chung J, Karkhanis V, Said S, Baiocchi RA."Protein Arginine Methyltransferase 5 Regulates WNT/β-Catenin Target Gene Expression in at Multiple Levels" .
December 2016 Smith E, Stiff A, Patton JT, Carson W, Lapalombella R, Baiocchi RA."BET Bromodomain Inhibition Selectively Targets the Epstein-Barr Virus Oncogene LMP1 While Promoting Virus-Specific, Adaptive Anti-Tumor Activity" .
December 2016 Karkhanis V, Alinari L, Mundy B, Caliguri M, Chen-Kiang S, Elemento O, Said S, Baiocchi RA."PRMT5 Targets Tumor Suppressor Micro RNAs to Regulate Cyclin D1 and c-MYC in Mantle Cell Lymphoma" .
December 2016 Makowski M, Ahmed E, Schlotter S, Pearson R, Kitzler R, Alvarnas JC, Rademacher JL, Wang Y, Little RF, Akpek G, Ayala, Devine SM, Kaplan LD, Noy A, Popat UR, Hsu JW, Morris LE, Thompson, Horowitz MH, Mendizabal AM, Levine AM, Krishnan A, Hade E, Hofmeister CC, Forman SJ, Navarro WH, Ambinder RF, Lozanski G, Baiocchi RA."Evaluation of Immune Recovery Following Autologous Hematopoietic Cell Transplantation in HIV-Related Lymphoma: Results of the BMT CTN 0803/AMC 071 Trial." .
April 2016 Banasavadi-Siddegowda YK, Russell L, Zhang J, Karkhanis VA, Imitola J, Baiocchi RA, Kaur B."PRMT5-PTEN molecular pathway regulates senescence and self reneal of glioblastoma stem-like cells" .

Softwares

January 2011 Baiocchi RA."AIDS/HIV Cancer Website"

Inventions and Patents

Immune Modulatory Properties of Silvestrol

A method for inducing apoptosis of primary central nervous system B cell lymphomas

Methods to treat or prevent viral-associated lymphoproliferative disorders with TGF-B antagonists

Methods and compositions for preventing Epstein-Barr associated disease

Identification and Use of Compounds to Inhibit PRMT5 Enzyme Activity for Cancer Therapeutics

Compositions and Methods for Regulating Immune Function

 

Presentations

Detection and treatment of EBV lymphoma in the SCID-hu mouse.

EBV-Associated lymphoproliferative disease in the hu-PBL-SCID mouse: Cykotine imbalances and implications for tumor growth.

Epstein-Barr virus-associated lymphoproliferative disease in the severe combined immune deficient human/mouse model: Prevention with low dose interleukin--2 supresses production of human interleukin-6 and interleukin-10.

The role of interleukin-15 in innate immunity.

FAS expression in primary central nervous system lymphoma of patients with the acquired immune deficiency syndrome.

Management of Hodgkin's Disease

Current approaches to post-transplant Lymphoproliferative Disease

Combination Antiviral Therapy for treatment of primary central nervous system lymphoma associated with the Epstein-Barr Virus: In Vivo Evaluation in an animal model.

Induction of the EBV thymidine kinase gene product to target antiviral therapy at EVB-associated malignancies.

Combination Antiviral Therapy to treat Epstein-Barr Virus-Associated Primary Central Nervous System Lymphoma

Post Transplant Lymphoproliferative Disease in Renal Transplantation

Advances in management of post transplant lymphoproliferative diseases.

Targeting lytic and latent gene products in EBV-associated malignancies.

Treatment of Epstien-Barr Virus-associated lymphoproliferative disorders with histone deacetylase inhibitors.

Targeting lytic gene products in EBV-positive lymphomas.

Developing strategies to target Epstien-Barr virus positive lymphomas.

Infection, Inflammation and Lymphoma

Modulation and Targeting of Viral Protiens in Epstein-Barr Virus-Associated Malignancies

Utilizing Research tools to care for patients with Cancer. Technology Enhanced Learning and Research

Vaccine approaches to treat Epstein-Barr Virus-Associated disease.

Combination Bortezomib and Rituximab to treat Mantle Cell Lymphoma

Overview of Baiocchi Laboratory Program for Viral Oncogenesis Program Annual Retreat

AIDS Malignancies

How to apply, interview, and negotiate contracts for a laboratory based academic Hematology Oncology position.

The Role of Translational Research in Patient Care

Translating basic science from the laboratory to the clinic

Targeting the Protein Arginine Methyltransferase Enzyme in Mantle Cell Lymphoma

Pharmacodynamics and pharmacology of chemotherapy regimins to treat HIV-associated lymphomas.

Developing Vaccine Strategies to Prevent EBV-Associated Lymphomas-Therapy Accelarated Program

AIDS malignancies

Leukemia Lymphoma Society

Finding and Negotiating a Laboratory-Based Academic Position in Hematology/Oncology

Overview of viral oncogenesis

Immune deficiency and cancer.

EBV infection promotes epigenetic silencing of tumor suppresor genes that alter the microenvironment.

PTLD Overview. Pathogenesis and Management

Management of PTLD at OSU

Management of Primary CNS PTLD at OSU

HIV and Cancer. Challenges and Opportunities.

Pennies for Patients Fund Drive

Animal Models of Disease. How do we know they apply to humans?

Vaccine Strategies to Prevent EBV-Associated Post Transplant lymphomas

Infection, Inflammation and Cancer

HIV/AIDS and Cancer

Discovery of small molecule inhibitors to target PRMT5 over expression in mantle cell lymphoma

HIV+ Lymphoma

Potential for a vaccine approach to prevention of EBV-associated malignancy

"Discovering Novel Targets for Mantle Cell Lymphoma"

Enzyme Protein Arginine Methyltransferase 5 (PRMT5) as a Target in MCL

Developing Strategies to Target Novel Pathways in Cancer PRMT5, Arginine Methylation and Cancer

Developing Strategies to Fund Research to Enhance Minority Patient Access to AMC Clinical Trials

Successful Research Panel

Mechanism of Viral Oncogenesis and EBV Associated Disease

"Targeting PRMT5 and Lymphoma"

Lymphoma Research Foundation, Ask the Doctor

HIV related Malignancies

Inventory Panel Discussion

HIV/AIDS and Cancer

Vaccine Strategies for Preventing EBV-associated Diseases

Identification and Use of Compounds to Inhibit PRMT5 Ensyme Activities for Cancer Therapeutics

Developing a new class of drug to target PRMT5 in Cancer"

Management of A Typical HUS

Impact of an Educational Initiative on Minority Volunteer Perceptions of Clinical Trials

Translating Basic Science Observations to Cancer Drug Development

Medical Scientists Training Program Faculty Round Table, The Ohio State University

HIV Associated Malignancies

Biological Sciences Scholars Seminar

Developing a novel class of epigenetic drug to target PRMT5 in cancer.

Developing a National Reputation as a Basic/Translational Scientist

Faculty advancement Mentoring and Engagement-no title

Lead Optimization of Novel Drugs to Target PRMT5 in Cancer

The many roads for a career in academic medicine

PRMT5

PRMT5

How to Build a Successful Research Program as a Clinician

Technology and Commercialization in Academic Medical Centers

PRMT5

Targeting PRMT5: A collaborative approach to drug discovery in academia. Merging academia with industry.�

 

Professional Activities

2008 - present Free Medical Clinic. Xenos / Youth for Christ Free Medical Clinic. Columbus, OH.
2008 - present AIDS Clinical Trials Unit and AIDS Malignancy Consortium Community Advisory Board. ACTU/AMC Community Advisory Board. Columbus, OH.
2009 - present Ohio ACP Students and Associates Abstract Competition. American College of Physicians Ohio Chapter. Columbus, OH.
2011 - present Cover Story and Photo. "HemOnc Today" Clinical News in Hematology and Oncology.
2011 - present Letter of Intent Review Process ad hoc member Research Evaluation and Decision Panel (REDP). Aids and Cancer Specimen Resource (ACSR).
2011 - present OSU Medical Center Annual Research Day Poster. The Ohio State University Medical Center.
2011 - present American Cancer Society's Institutional Rsearch Grant. American Cancer Society.
2008 - 2010 OSU Post Transplant Lymphoproliferative Disorder Focus Group. PTLD Focus Group. Columbus, OH.
 

Unpublished Works

Targeting Protein Arginine Methyltransferase 5 (PRMT5) Enzyme Over Expression in High Grade Astrocytomas

Complex Karyotype is Associated with Shortened Progression-Free Survival and Increased Cumulative Incidence of Relapse Following Autologous Stem Cell Transplantation for Mantle Cell Lymphoma

Phase I Feasibility Trial of Cyclophosphamide, Alvocidib (Flavopiridol) and Rituximab (CAR) in Patients with High-Risk B-cell Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Flavopiridol Can Be Safely Administered Using a Pharmacologically Derived Schedule and Demonstrates Activity In Relapsed and Refractory Non-Hodgkin's Lymphoma

Silvestrol modulated direct and indirect anti-tumor activity against Epstein-Barr Virus-driven lymphoproliferative disease

omplete Response to Induction Therapy in Patients with Myc+ and Double Hit non-Hodgkin’s Lymphoma is Associated with Prolonged Progression-Free Survival

Complex karyotype is associated with aggressive disease and shortened progression-free survival in patients with newly diagnosed mantle cell lymphoma

PRMT5 inhibition induces death of lymphoma cells through reactivation of the retinoblastoma tumor suppressor pathway and silencing of the PRC2 complex